30
Participants
Start Date
August 14, 2024
Primary Completion Date
May 8, 2025
Study Completion Date
May 8, 2025
Oral EVO756
Oral EVO756, once daily
OptiSkin Medical, New York
Allergy and Clinical Immunology Associates, Pittsburgh
Chesapeake Clinical Research, Inc, White Marsh
Aeroallergy Research Laboratories of Savannah, Inc., Savannah
Advanced Clinical Research Institute, Tampa
Cahaba Dermatology & Skin Health Center, LLC, Birmingham
Bexley Dermatology Research, Bexley
Indiana Clinical Trials Center, P.C., Plainfield
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Southern Indiana Clinical Trials, New Albany
Red River Research Partners, Fargo
DelRicht Research, Baton Rouge
Allergy, Asthma, and Clinical Research Center, Oklahoma City
Austin Institute for Clinical Research, Pflugerville
Treasure Valley Medical Research, Boise
California Allergy and Asthma Medical Group, Los Angeles
West Dermatology Research Center, San Diego
Integrative Skin Science and Research, Sacramento
Lead Sponsor
Evommune, Inc.
INDUSTRY